← Back to Search

Selective Serotonin Reuptake Inhibitor

Escitalopram for Brain Tumor

Phase 2
Recruiting
Led By Nicole A Shonka, MD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Performance status ECOG 0-2 or equivalent
Patients must be age ≥19 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 17 weeks
Awards & highlights

Study Summary

This trial will study the effects of SSRIs on grade IV glioma patients. Changes in cognition and psychosocial factors will be measured from before treatment to 17 weeks after treatment.

Who is the study for?
This study is for adults over 19 with a specific brain tumor called Grade IV glioma, who are about to start or are currently receiving chemo and/or radiation. They should be able to perform daily activities (ECOG 0-2), have a life expectancy over 6 months, and not be pregnant. Those with severe kidney issues, depression or anxiety, visual field defects, or intolerance to similar medications cannot join.Check my eligibility
What is being tested?
The trial tests Escitalopram Oral Capsules on patients with grade IV glioma over approximately 17 weeks. It aims to see how the drug affects cognition and psychosocial factors in these patients during their treatment period.See study design
What are the potential side effects?
Escitalopram may cause side effects like nausea, sleepiness or insomnia, increased sweating, fatigue, dry mouth and sexual dysfunction. Some people might also experience emotional changes such as nervousness or mood swings.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform daily activities.
Select...
I am 19 years old or older.
Select...
I have been diagnosed with a Grade IV brain tumor.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~17 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 17 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Characterize the degree of change in cognition
Characterize the degree of change in cognition and brain function
Determine the degree of change in psychosocial functions

Trial Design

1Treatment groups
Experimental Treatment
Group I: EscitalopramExperimental Treatment1 Intervention
This is an open-label study. Escitalopram will be administered to all participants as 10 mg capsules to be taken by mouth daily for 90 days.

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
535 Previous Clinical Trials
1,143,886 Total Patients Enrolled
Nicole ShonkaLead Sponsor
Nicole A Shonka, MDPrincipal InvestigatorUniversity of Nebraska
3 Previous Clinical Trials
46 Total Patients Enrolled

Media Library

Escitalopram (Selective Serotonin Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03728673 — Phase 2
Brain Tumor Research Study Groups: Escitalopram
Brain Tumor Clinical Trial 2023: Escitalopram Highlights & Side Effects. Trial Name: NCT03728673 — Phase 2
Escitalopram (Selective Serotonin Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03728673 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for individuals to join this experiment at the present?

"According to the clinicaltrials.gov webpage, this medical research project is currently looking for participants. This experiment was initially listed on March 6th 2019 and has recently been amended on July 27th 2022."

Answered by AI

Have prior investigations occurred involving Escitalopram Oral Tablet?

"At this moment, 23 trials are underway to research Escitalopram Oral Tablet. 5 of those have reached Phase 3. The bulk of these experiments take place in Cincinnati, Ohio; however, 45 sites across the US are running similar studies for the same treatment."

Answered by AI

Is Escitalopram Oral Tablet an innocuous medication for those taking it?

"Based on our assessment, escitalopram oral tablets have been rated a 2 out of 3 in terms of safety. This reflects their Phase 2 trial status with limited data supporting its efficacy but some that attest to its safety."

Answered by AI

What is the aggregate population size of participants enrolled in this research endeavor?

"Affirmative. The clinical trial details featured on clinicaltrials.gov suggest that recruitment is still in progress for this medical study, which was first published on March 6th 2019 and recently updated on July 27th 2022. A total of 20 participants are needed from a single location."

Answered by AI
~2 spots leftby Dec 2024